Search Results

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (“Taconic” or the “Company”) to Avista Capital Partners (“Avista”).

Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.

Taconic Biosciences has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors known to confound results in antibody-based therapy studies.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.

Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.